Early clinical trials in patients with recurrent or metastatic HNSCC, for whom the chances of improvement after platinum‐based chemotherapy have been poor, initially showed impressive clinical results using the anti‐PD‐1 antibodies nivolumab or pembrolizumab [3, 4]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.